An observational study in Atopy, Primary Immunodeficiency and Autoimmunity, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 2 sites in United States. Open to participants aged 1 Day to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 11 under way, none of them phase 3. Primary Immunodeficiency Diseases · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2017, is one of 11 observational ones, and was the 10th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →11 of the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 4 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Italy, Turkey
Ages 1 days–99 yrs
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 days–90 yrs · Healthy volunteers
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 1 Day to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 4 1
First in 1995; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 137 across 77 observational studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 8 across the 5 interventional studies, 1,190 across the 11 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
2 of the studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04864886National Institute of Allergy and Infectious Diseases (NIAID)Metabolic Profiling of Immune Responses in Immune-mediated Diseases | 2027-06-30 |
| NCT05189925National Institute of Allergy and Infectious Diseases (NIAID)NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.
Objective:
To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.
Eligibility:
Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children's National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives
Design:
Researchers will study participant's DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant's DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.
Participants will receive results that:
Some genetic information we return to participants may be of uncertain importance.
If genetic test results are unrelated to the participant's NIH evaluations, then we will not typically report:
The samples and data will be saved for future research.
Personal data will be kept as private as possible.
If future studies need new information, participants may be contacted.
Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) use next-generation sequencing technologies to help determine genetic contributions to immune diseases. These efforts have increased rates of molecular diagnosis for a subset of NIAID
participants as well as uncovered fundamental insights into the cellular and signaling pathways in host defense and immune regulation.
Despite these successes, analysis and interpretation of genomic data remain a substantial challenge. Simply, researchers do not understand the functional and clinical consequences of most human genetic variation. This is true at NIAID and across the intramural research program. Making progress in this area requires a coordinated, systematic, and transparent approach to clinical genomics research.
This protocol is specific to genetic testing and explicitly aims to both strengthen clinical care and enhance research throughout participating programs at the NIH. Probands will provide biological specimens for genetic testing and will be required to be enrolled on a primary protocol, which will execute the primary clinical and research evaluations. This protocol serves as a vehicle for a
programmatic effort that includes standardized phenotyping, test ordering through the Clinical Research Information System (CRIS), sample collection and isolation, nucleic acid analysis, bioinformatics, clinical interpretation, reporting in CRIS, genetic counseling, and supporting effective use of genomics as a research tool throughout the intramural program. Genetic testing results and data (upon request) will be shared with the research teams for protocols on which a given participant is co-enrolled. Overall, increased process standardization will support data integrity and efficiency while still accommodating the need for investigator flexibility.
The criteria were revised on the registry on Oct 22, 2026. See what changed
Probands and their biological relatives (primarily clinical), recruited from NIAID protocols (both at the NIH and CNHS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must fulfill one of the following criteria:
To complete surveys and interviews:
EXCLUSION CRITERIA:
Any condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
Select internal controls
Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
Identifying novel genetic defects associated with immune disorders
Identifying novel genetic defects associated with immune disorders
Time frame: Upon analysis of genomic data
Identifying novel clinical phenotypes associated with established genetic defects
Identifying novel clinical phenotypes associated with established genetic defects
Time frame: Upon analysis of genomic data
Identifying established genetic disorders of the immune system
Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases
Time frame: Upon analysis of genomic data
Evidence base for how to improve clinical genomic services on this protocol and related programs.
Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.
Time frame: 5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews
Plan to share: Undecided — The PI is on maternity leave and will discuss when they return
Started Jul 2017 (actual). Primary completion is estimated for Jul 2042, 299 months after the start.
Of 50 observational studies under Primary Immunodeficiency Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 30. This study's planned 299 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2029 → Jul 2042 and completion Dec 2029 → Jul 2042.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →
National Institute of Allergy and Infectious Diseases (NIAID) →